{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:09:24Z","timestamp":1793329764134,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Surg Oncol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13193-023-01773-1","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:02:31Z","timestamp":1685433751000},"page":"478-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular Subtypes and Ki-67 index in Breast Carcinoma with Special Emphasis on Triple Negative Breast Cancer. A 3-year Study in a Tertiary Care Center"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3164-8219","authenticated-orcid":false,"given":"Shweta","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa V","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"1","key":"1773_CR1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrclinonc.2011.178","volume":"9","author":"A Prat","year":"2011","unstructured":"Prat A, Ellis MJ, Perou CM (2011) Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 9(1):48\u201357","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1773_CR2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/PAP.0b013e318220f5d1","volume":"18","author":"EA Rakha","year":"2011","unstructured":"Rakha EA, Ellis IO (2011) Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol 18(4):255\u2013267","journal-title":"Adv Anat Pathol"},{"key":"1773_CR3","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1158\/1055-9965.EPI-12-0474","volume":"21","author":"R Haque","year":"2012","unstructured":"Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J et al (2012) Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 21:1848\u20131855","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"1773_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/bcr2607","volume":"12","author":"EA Rakha","year":"2010","unstructured":"Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR et al (2010) Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12(4):207","journal-title":"Breast Cancer Res"},{"key":"1773_CR5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.20892\/j.issn.2095-3941.2016.0066","volume":"13","author":"NA Soliman","year":"2016","unstructured":"Soliman NA, Yussif SM (2016) Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 13:496\u2013504","journal-title":"Cancer Biol Med."},{"key":"1773_CR6","doi-asserted-by":"crossref","first-page":"003293","DOI":"10.1101\/cshperspect.a003293","volume":"3","author":"CM Perou","year":"2011","unstructured":"Perou CM, B\u00f8rresen-Dale AL (2011) Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol. 3:003293","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"1773_CR7","doi-asserted-by":"crossref","first-page":"e1000279","DOI":"10.1371\/journal.pmed.1000279","volume":"7","author":"FM Blows","year":"2010","unstructured":"Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J et al (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279","journal-title":"PLoS Med"},{"key":"1773_CR8","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329\u20132334","journal-title":"Clin Cancer Res"},{"key":"1773_CR9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10549-016-3817-9","volume":"157","author":"S Bustreo","year":"2016","unstructured":"Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F et al (2016) Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat 157:363\u2013371","journal-title":"Breast Cancer Res Treat"},{"key":"1773_CR10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4137\/CMO.S18006","volume":"8","author":"Z Inic","year":"2014","unstructured":"Inic Z, Zegarac M, Inic M, Markovic I, Kozomara Z, Djurisic I et al (2014) Difference between luminal A and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information. Clin Med Insights Oncol 8:107\u2013111","journal-title":"Clin Med Insights Oncol"},{"key":"1773_CR11","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart- Gebhart M et al (2015) Tailoring therapies\u2013improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26:1533\u20131546","journal-title":"Ann Oncol"},{"key":"1773_CR12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-007-9632-6","volume":"109","author":"RC Millikan","year":"2008","unstructured":"Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123\u2013139","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"1773_CR13","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736\u20131747","journal-title":"Ann Oncol"},{"issue":"4","key":"1773_CR14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/ERC-10-0136","volume":"17","author":"MT Weigol","year":"2010","unstructured":"Weigol MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat cancer 17(4):245\u2013262","journal-title":"Endocr Relat cancer"},{"key":"1773_CR15","doi-asserted-by":"crossref","unstructured":"Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006; 4 Suppl 3: S1\u201322; quiz S23\u20134","DOI":"10.6004\/jnccn.2006.2003"},{"issue":"3","key":"1773_CR16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5306\/wjco.v5.i3.382","volume":"5","author":"DC Zaha","year":"2014","unstructured":"Zaha DC (2014) Significance of immunohistochemistry in breast cancer. World J Clin Oncol 5(3):382\u2013392","journal-title":"World J Clin Oncol"},{"key":"1773_CR17","first-page":"155","volume":"11","author":"DC Allred","year":"1998","unstructured":"Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155\u2013168","journal-title":"Mod Pathol"},{"key":"1773_CR18","first-page":"461","volume-title":"Diseases of the Breast","author":"GM Clark","year":"1996","unstructured":"Clark GM (1996) Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M (eds) Diseases of the Breast. Lippincott\u2013 Raven, Philadelphia, pp 461\u2013485"},{"issue":"1","key":"1773_CR19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1309\/HCF035N9WK40ETJ0","volume":"123","author":"LC Collins","year":"2005","unstructured":"Collins LC, Botero ML, Schnitt SJ (2005) Bimodal frequency distribution of Estrogen Receptor immunohistochemical staining results in breast cancer. Am J Clin Pathol 123(1):16\u201320","journal-title":"Am J Clin Pathol"},{"key":"1773_CR20","unstructured":"ASCO\u2011CAP HER2\/neu Test Guideline Recommendations. College of American Pathologists; 2013."},{"key":"1773_CR21","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of american pathologists clinical practice guideline update. J Clin Oncol 31:3997\u20134013","journal-title":"J Clin Oncol"},{"issue":"21","key":"1773_CR22","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc 295(21):2492\u20132502","journal-title":"J Am Med Assoc"},{"issue":"1","key":"1773_CR23","first-page":"35","volume":"4","author":"K Subik","year":"2010","unstructured":"Subik K, Lee JF, Baxter L et al (2010) The expression patterns of ER, PR, HER2, CK5\/6, EGFR, KI-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer Basic Clin Res 4(1):35\u201341","journal-title":"Breast Cancer Basic Clin Res"},{"issue":"10","key":"1773_CR24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MCU Cheang","year":"2009","unstructured":"Cheang MCU, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736\u2013750","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"1773_CR25","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol 24(9):2206\u20132223","journal-title":"Ann Oncol"},{"key":"1773_CR26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amsu.2019.11.021","volume":"49","author":"FK Al-thoubaity","year":"2020","unstructured":"Al-thoubaity FK (2020) Molecular classification of breast cancer: A retrospective cohort study. Annals Med Surg 49:44\u20138","journal-title":"Annals Med Surg"},{"key":"1773_CR27","unstructured":"Saudi Cancer Registry, Cancer Incidence Report, (2010) Saudi Arabia, Riyadh (KSA), 2014"},{"issue":"1","key":"1773_CR28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/1658-631X.112908","volume":"1","author":"M Shawarby","year":"2013","unstructured":"Shawarby M, Al-Tamimi D, Ahmed A (2013) Molecular classification of breast cancer: an overview with emphasis on ethnic variations and future perspectives. Saudi J Med Sci 1(1):14\u201319","journal-title":"Saudi J Med Sci"},{"issue":"27_suppl","key":"1773_CR29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/jco.2011.29.27_suppl.219","volume":"29","author":"I Mehdi","year":"2011","unstructured":"Mehdi I, Abdulmasood AA, Bahrani BJA (2011) Breast cancer molecular subtypes in Omani patients: correlation with age, histology, stage distribution, and outcome\u2014an anaylsis of 542 cases. J. Clin. Oncol. 29(27_suppl):219\u2013219","journal-title":"J. Clin. Oncol."},{"key":"1773_CR30","unstructured":"L.A.G. Ries, D. Melbert, M. Krapcho, et al (2008) SEER Cancer Statistics Review, 1975\u20132005, National Cancer Institute, Bethesda, MD"},{"key":"1773_CR31","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2003.09.099","volume":"21","author":"VJ Bardou","year":"2003","unstructured":"Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973\u20131979","journal-title":"J Clin Oncol"},{"key":"1773_CR32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1365-2168.2000.01402.x","volume":"87","author":"V Speirs","year":"2000","unstructured":"Speirs V, Kerin MJ (2000) Prognostic significance of oestrogen receptor beta in breast cancer. Br J Surg 87:405\u2013409","journal-title":"Br J Surg"},{"key":"1773_CR33","first-page":"529","volume":"59","author":"H Dotzlaw","year":"1999","unstructured":"Dotzlaw H, Leygue E, Watson PH, Murphy LC (1999) Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res 59:529\u2013532","journal-title":"Cancer Res"},{"key":"1773_CR34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/path.1436","volume":"201","author":"GP Skliris","year":"2003","unstructured":"Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K et al (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201:213\u2013220","journal-title":"J Pathol"},{"issue":"4","key":"1773_CR35","first-page":"287","volume":"8","author":"R Yadav","year":"2016","unstructured":"Yadav R, Sen R, Chauhan P (2016) ER, PR, HER2\/NEU Status and relation to Clinicopathological Factors in Breast carcinoma. Int J Pharm Pharm Sci 8(4):287\u2013290","journal-title":"Int J Pharm Pharm Sci"},{"issue":"1","key":"1773_CR36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11596-013-1082-2","volume":"33","author":"HT Cheng","year":"2013","unstructured":"Cheng HT, Huang T, Wang W et al (2013) Clinicopathological features of breast cancer with different molecular subtypes in Chinese women. J Huazhong Univ Sci Technolog Med Sci 33(1):117\u2013121","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"3","key":"1773_CR37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.15406\/icpjl.2018.06.00175","volume":"6","author":"N Atif","year":"2018","unstructured":"Atif N, Khalid M, Chughtai O (2018) Role of immunohistochemical markers in breast cancer and their correlation with grade of tumour, our experience. Int Clin Pathol J 6(3):141\u2013145","journal-title":"Int Clin Pathol J"},{"key":"1773_CR38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/njs.NJS_2_18","volume":"24","author":"P Chand","year":"2018","unstructured":"Chand P, Garg A, Singla V, Rani N (2018) Evaluation of immunohistochemical profile of breast cancer for prognostics and therapeutic use. Niger J Surg 24:100\u2013106","journal-title":"Niger J Surg"},{"key":"1773_CR39","first-page":"291","volume":"54","author":"PH Giangrande","year":"1999","unstructured":"Giangrande PH, McDonnell DP (1999) The A and B isoforms of the human progesterone receptor: Two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 54:291\u2013313","journal-title":"Recent Prog Horm Res"},{"key":"1773_CR40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1677\/erc.0.0080047","volume":"8","author":"DC Allred","year":"2001","unstructured":"Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8:47\u201361","journal-title":"Endocr Relat Cancer"},{"key":"1773_CR41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1677\/erc.0.0080011","volume":"8","author":"N Prenzel","year":"2001","unstructured":"Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11\u201331","journal-title":"Endocr Relat Cancer"},{"key":"1773_CR42","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3892\/etm.2010.133","volume":"1","author":"R Nishimura","year":"2010","unstructured":"Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N (2010) Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 1:747\u2013754","journal-title":"Exp Ther Med"},{"key":"1773_CR43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","volume":"11","author":"R Yerushalmi","year":"2010","unstructured":"Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174\u2013183","journal-title":"Lancet Oncol"},{"key":"1773_CR44","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","volume":"96","author":"E Azambuja","year":"2007","unstructured":"Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V et al (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer. 96:1504\u201313","journal-title":"Br J Cancer."},{"issue":"4","key":"1773_CR45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.breast.2008.02.002","volume":"17","author":"R Stuart-Harris","year":"2008","unstructured":"Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17(4):323\u2013334","journal-title":"Breast"},{"key":"1773_CR46","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 351:2817\u20132826","journal-title":"N Engl J Med"},{"key":"1773_CR47","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al (2006) Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726\u20133734","journal-title":"J Clin Oncol"},{"issue":"2","key":"1773_CR48","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10549-013-2560-8","volume":"139","author":"EC Inwald","year":"2013","unstructured":"Inwald EC, Klinkhammer-Schalke M, Hofst\u00e4dter F et al (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139(2):539\u2013552","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1773_CR49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12282-009-0161-5","volume":"17","author":"R Nishimura","year":"2010","unstructured":"Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N (2010) Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 17(4):269\u2013275","journal-title":"Breast Cancer"},{"key":"1773_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4137\/CMO.S18006","volume":"8","author":"Inic","year":"2014","unstructured":"Inic et al (2014) Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. Clin Med Insights: Oncol 8:107\u2013111. https:\/\/doi.org\/10.4137\/CMO.S18006","journal-title":"Clin Med Insights: Oncol"},{"issue":"1","key":"1773_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00428-014-1593-7","volume":"465","author":"D Vuong","year":"2014","unstructured":"Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR (2014) Molecular classification of breast cancer. Virchows Arch 465(1):1\u201314","journal-title":"Virchows Arch"},{"issue":"3","key":"1773_CR52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1055-9965.EPI-06-0806","volume":"16","author":"XR Yang","year":"2007","unstructured":"Yang XR, Sherman ME, Rimm DL et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomark Prev 16(3):439\u2013443","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"1773_CR53","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3816\/CBC.2010.n.038","volume":"10","author":"CS Vallejos","year":"2010","unstructured":"Vallejos CS, Gomez HL, Cruz WR et al (2010) Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Canc 10(4):294\u2013300","journal-title":"Clin Breast Canc"},{"issue":"2","key":"1773_CR54","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1111\/ajco.12034","volume":"10","author":"A Fourati","year":"2014","unstructured":"Fourati A, Boussen H, El May MV et al (2014) Descriptive analysis of molecular subtypes in Tunisian breast cancer. Asia, Pac J Clin Oncol 10(2):e69-74","journal-title":"Asia, Pac J Clin Oncol"},{"key":"1773_CR55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2407-10-223","volume":"10","author":"DM Al Tamimi","year":"2010","unstructured":"Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA (2010) Protein expression profile and prevalence pattern of the molecular classes of breast cancer\u2013taa Saudi population-based study. BMC Canc. 10:223","journal-title":"BMC Canc."},{"issue":"1","key":"1773_CR56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.anndiagpath.2013.10.005","volume":"18","author":"BH Elesawy","year":"2014","unstructured":"Elesawy BH, Abd El Hafez A, Shawky Ael A, Arafa M (2014) Immunohistochemistry based subtyping of breast carcinoma in Egyptian women: a clinicopathologic study on 125 patients. Ann Diagn Pathol 18(1):21\u201326","journal-title":"Ann Diagn Pathol"},{"issue":"12","key":"1773_CR57","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1158\/1055-9965.EPI-17-0611","volume":"26","author":"M Ellingjord-Dale","year":"2017","unstructured":"Ellingjord-Dale M, Vos L, Hjerkind KV et al (2017) Alcohol, physical activity, smoking, and breast cancer subtypes in a large, nested case-control study from the Norwegian breast cancer screening program. Cancer Epidemiol Biomark Prev 26(12):1736\u20131744","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1773_CR58","first-page":"340","volume":"2","author":"SB Suvarchala","year":"2011","unstructured":"Suvarchala SB, Nageshwararao R (2011) Carcinoma Breast-Histopathological and hormone receptors correlation. J Biosci Tech 2:340\u2013348","journal-title":"J Biosci Tech"},{"issue":"3","key":"1773_CR59","first-page":"295","volume":"2","author":"M Bhagat Vasudha","year":"2012","unstructured":"Bhagat Vasudha M, Jha Bharti M, Patel PR (2012) Correlation of hormonal receptor and her2 neu expression in breast cancer: A study at tertiary care hospital in south Gujarat. Natl J Med Res 2(3):295\u2013298","journal-title":"Natl J Med Res"},{"issue":"17","key":"1773_CR60","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1200\/JCO.2010.32.3550","volume":"29","author":"I Jatoi","year":"2011","unstructured":"Jatoi I, Anderson WF, Jeong J-H, Redmond CK (2011) Breast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects. J Clin Oncol 29(17):2301\u20132304","journal-title":"J Clin Oncol"},{"key":"1773_CR61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2016.12.006","volume":"110","author":"PG Tsoutsou","year":"2017","unstructured":"Tsoutsou PG, Vozenin M-C, Durham A-D, Bourhis J (2017) How could breast cancer molecular features contribute to locoregional treatment decision making? Crit Rev Oncol Hematol 110:43\u201348","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"1773_CR62","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ejso.2011.07.001","volume":"37","author":"P Sanpaolo","year":"2011","unstructured":"Sanpaolo P, Barbieri V, Genovesi D (2011) Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early-stage breast cancer: A retrospective clinical study. Eur J Surg Oncol 37(10):876\u2013882","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"1773_CR63","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s13277-013-1260-7","volume":"35","author":"A Garc\u00eda Fern\u00e1ndez","year":"2014","unstructured":"Garc\u00eda Fern\u00e1ndez A, Chabrera C, Garc\u00eda Font M et al (2014) Mortality and recurrence patterns of breast cancer patients diagnosed under a screening programme versus comparable non-screened breast cancer patients from the same population: analytical survey from 2002 to 2012. Tumor Biol 35(3):1945\u20131953","journal-title":"Tumor Biol"},{"issue":"9472","key":"1773_CR64","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365(9472):1687\u20131717","journal-title":"Lancet."},{"issue":"2","key":"1773_CR65","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.semradonc.2011.12.001","volume":"22","author":"F van der Leij","year":"2012","unstructured":"van der Leij F, Elkhuizen PHM, Bartelink H, van de Vijver MJ (2012) Predictive Factors for Local Recurrence in Breast Cancer. Semin Radiat Oncol 22(2):100\u2013107","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"1773_CR66","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/srao.2002.35252","volume":"12","author":"BG Haffty","year":"2002","unstructured":"Haffty BG (2002) Molecular and genetic markers in the local-regional management of breast cancer. Semin Radiat Oncol 12(4):329\u2013340","journal-title":"Semin Radiat Oncol"},{"issue":"28","key":"1773_CR67","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1200\/JCO.2008.21.7075","volume":"27","author":"EKA Millar","year":"2009","unstructured":"Millar EKA, Graham PH, O\u2019Toole SA et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27(28):4701\u20134708","journal-title":"J Clin Oncol"},{"issue":"10","key":"1773_CR68","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","volume":"28","author":"KD Voduc","year":"2010","unstructured":"Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684\u20131691","journal-title":"J Clin Oncol"},{"issue":"29","key":"1773_CR69","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2011.36.1105","volume":"29","author":"ND Arvold","year":"2011","unstructured":"Arvold ND, Taghian AG, Niemierko A et al (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29(29):3885\u20133891","journal-title":"J Clin Oncol"},{"issue":"5","key":"1773_CR70","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ijrobp.2009.12.011","volume":"77","author":"JM Albert","year":"2010","unstructured":"Albert JM, Gonzalez-Angulo AM, Guray M et al (2010) Estrogen\/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a, bN0 Breast Cancer. Int J Radiat Oncol 77(5):1296\u20131302","journal-title":"Int J Radiat Oncol"},{"issue":"14","key":"1773_CR71","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","volume":"26","author":"PL Nguyen","year":"2008","unstructured":"Nguyen PL, Taghian AG, Katz MS et al (2008) Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy. J Clin Oncol 26(14):2373\u20132378","journal-title":"J Clin Oncol"},{"issue":"6","key":"1773_CR72","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1158\/1055-9965.EPI-09-0096","volume":"18","author":"Lin","year":"2009","unstructured":"Lin et al (2009) Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia. Cancer Epidemiol Biomarkers Prev 18(6):1807\u20131814","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1773_CR73","unstructured":"Lakhani SR, Ellis IO, Schnitt SJ, et al (2012) WHO Classification of Tumours of the Breast"},{"issue":"7","key":"1773_CR74","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750\u20132767","journal-title":"J Clin Invest"},{"issue":"14","key":"1773_CR75","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1200\/JCO.2009.24.2495","volume":"28","author":"KE Malone","year":"2010","unstructured":"Malone KE, Begg CB, Haile RW et al (2010) Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated with Carrying a Mutation in BRCA1 or BRCA2. J Clin Oncol 28(14):2404\u20132410","journal-title":"J Clin Oncol"},{"issue":"1","key":"1773_CR76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/cge.12270","volume":"85","author":"N Tun","year":"2014","unstructured":"Tun N, Villani G, Ong K, Yoe L, Bo Z (2014) Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet 85(1):43\u201348","journal-title":"Clin Genet"},{"issue":"16","key":"1773_CR77","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med 353(16):1673\u20131684","journal-title":"N Engl J Med"},{"issue":"36","key":"1773_CR78","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","volume":"24","author":"BG Haffty","year":"2006","unstructured":"Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652\u20135657","journal-title":"J Clin Oncol"},{"issue":"2","key":"1773_CR79","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1055-9965.EPI-10-1016","volume":"20","author":"L Bessonova","year":"2011","unstructured":"Bessonova L, Taylor TH, Mehta RS, Zell JA, Anton-Culver H (2011) Risk of a Second Breast Cancer Associated with Hormone-Receptor and HER2\/neu Status of the First Breast Cancer. Cancer Epidemiol Biomarkers Prev 20(2):389\u2013396","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"1773_CR80","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","volume":"293","author":"P Kumar","year":"2016","unstructured":"Kumar P, Aggarwal R (2016) An overview of triple-negative breast cancer. Arch Gynecol Obstet 293(2):247\u2013269","journal-title":"Arch Gynecol Obstet"},{"issue":"10","key":"1773_CR81","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","volume":"65","author":"MJ Wieduwilt","year":"2008","unstructured":"Wieduwilt MJ, Moasser MM (2008) The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cell Mol Life Sci 65(10):1566\u20131584","journal-title":"Cell Mol Life Sci"},{"issue":"6797","key":"1773_CR82","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747\u2013752","journal-title":"Nature"},{"issue":"19","key":"1773_CR83","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 98(19):10869\u201310874","journal-title":"Proc Natl Acad Sci."},{"issue":"14","key":"1773_CR84","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418\u20138423","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"1773_CR85","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2009.22.8775","volume":"28","author":"J Staaf","year":"2010","unstructured":"Staaf J, Ringn\u00e9r M, Vallon-Christersson J et al (2010) Identification of subtypes in human epidermal growth factor receptor 2\u2013positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 28(11):1813\u20131820","journal-title":"J Clin Oncol"},{"issue":"4785","key":"1773_CR86","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235(4785):177\u2013182","journal-title":"Science"},{"key":"1773_CR87","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4757-3147-7_4","volume":"103","author":"MD Pegram","year":"2000","unstructured":"Pegram MD, Konecny G, Slamon DJ (2000) The molecular and cellular biology of HER2\/neu gene amplification\/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103:57\u201375","journal-title":"Cancer Treat Res"},{"issue":"1","key":"1773_CR88","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.soc.2017.08.005","volume":"27","author":"MF Simona","year":"2018","unstructured":"Simona MF, Sciallis A, Jeruss JS (2018) Molecular subtypes and local-regional control of breast cancer. Surg Oncol Clin N Am 27(1):95\u2013120","journal-title":"Surg Oncol Clin N Am"}],"container-title":["Indian Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-023-01773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13193-023-01773-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-023-01773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T09:58:20Z","timestamp":1746439100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13193-023-01773-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1007\/s13193-023-01773-1","relation":{},"ISSN":["0975-7651","0976-6952"],"issn-type":[{"value":"0975-7651","type":"print"},{"value":"0976-6952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"20 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and\/or Institutional Review Board (IRB) Approval"}},{"value":"All the authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.The authors have no financial or proprietary interests in any material discussed in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}